Timing of Corticosteroid Therapy Is Critical to Prevent Retinal Ganglion Cell Loss in Experimental Optic Neuritis | Zendy

Mahasweta Dutt | Zendy; Philomela Tabuena | Zendy; Elvira Ventura | Zendy; Abdolmohamad Rostami | Zendy; Kenneth S. Shindler | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Timing of Corticosteroid Therapy Is Critical to Prevent Retinal Ganglion Cell Loss in Experimental Optic Neuritis

Author(s) -

Mahasweta Dutt,

Philomela Tabuena,

Elvira Ventura,

Abdolmohamad Rostami,

Kenneth S. Shindler

Publication year - 2010

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.09-4009

Subject(s) - optic neuritis , medicine , optic nerve , retinal ganglion cell , methylprednisolone , dexamethasone , corticosteroid , experimental autoimmune encephalomyelitis , ophthalmology , multiple sclerosis , anesthesia , surgery , immunology

Acute vision loss from optic neuritis typically resolves; however, recovery is often not complete. Permanent vision loss from retinal ganglion cell (RGC) death occurs in 40% to 60% of patients. Current therapy (high-dose corticosteroids) speeds recovery but does not change final visual outcomes. Here the authors examined whether corticosteroids administered early in the disease course can prevent RGC loss in experimental optic neuritis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research